Long-acting Monoclonal Antibodies Market

Long-acting Monoclonal Antibodies Market Outlook 2032

The global long-acting monoclonal antibodies market size was USD XX Billion in 2023 and is projected to reach USD XX Billion by 2032, expanding at a CAGR of XX% during 2024–2032. The market growth is attributed to the increasing demand for innovative therapeutic solutions.

Growing emphasis on personalized medicine and targeted therapies is attributed to the high adoption of advanced long-acting monoclonal antibodies, which further boosts the market. Long-acting monoclonal antibodies are increasingly being tailored to individual patient needs for effective treatment outcomes and improved patient satisfaction. Moreover, the rising adoption of monoclonal antibody therapies further drives the demand for long-acting monoclonal antibodies.

• According to a report published by the National Library of Medicine on September 6, 2022, showing that 162 antibody therapies were approved by at least one regulatory agency worldwide. The US has approved 122 therapies, followed by Europe with 114, Japan with 82, and China with 73. 
  

  Get Free Sample Report
  

Impact of Artificial Intelligence (AI) in Long-acting Monoclonal Antibodies Market

The use of artificial intelligence is likely to boost the long-acting monoclonal antibodies market. AI-driven algorithms and machine learning techniques are increasingly being utilized to analyze vast amounts of biomedical data to accelerate the identification and validation of potential drug targets. Furthermore, AI-powered platforms enable the design of novel long-acting monoclonal antibodies with improved pharmacokinetic properties and therapeutic efficacy.

Long-acting Monoclonal Antibodies Market Dynamics

Get Free Sample Report

Major Drivers

Growing prevalence of chronic diseases, particularly autoimmune disorders and cancer is projected to boost the market. Long-acting monoclonal antibodies offer targeted treatment options that specifically modulate the immune system or target cancer cells. For instance, according to a report published by the WHO on February 1, 2024, there were an estimated 20 million new cancer cases in 2022. Moreover, the convenience of few injections and improved patient compliance associated with long-acting formulations further boost the market during the forecast period.

Existing Restraints

High cost associated with the development and production of these therapies is expected to hinder the market. The complex manufacturing processes involved in producing monoclonal antibodies and stringent regulatory requirements and quality control measures make these antibodies expansive. Furthermore, the risk of adverse events and safety concerns of long-acting monoclonal antibodies hampers the market.

Emerging Opportunities

­Increasing investment in R&D activities is expected to create immense opportunities for the players competing in the market. Pharmaceutical companies are focusing on the development of novel long-acting monoclonal antibody formulations to expand their consumer base. Moreover, advancements, such as antibody engineering and protein modification techniques, are enabling the design of next-generation long-acting monoclonal antibodies with optimized drug characteristics, thereby propelling the market.

Scope of the Long-acting Monoclonal Antibodies Market Report

The market report includes an assessment of the market trends, segments, and regional markets. Overview and dynamics are included in the report.

Long-acting Monoclonal Antibodies Market Segment Insights

Source Type Segment Analysis

Based on source type, the long-acting monoclonal antibodies market is divided into chimeric, humanized, murine, human, and others. The humanized segment held a major share of the market in 2023, as they are designed to reduce the risk of immunogenicity and enhance the antibodies compatibility with the human immune system.

Humanized antibodies are being widely used for their favorable pharmacokinetic properties and reduced risk of adverse reactions as compared to murine or chimeric antibodies. Moreover, advancements in antibody engineering technologies facilitate the development of highly specific antibodies targeting a wide range of therapeutic indications, which further boosts their demand.

The human segment is expected to expand at a significant growth rate in the coming years, owing to their reduced immunogenicity, and improved pharmacokinetics. Human monoclonal antibodies closely mimic the body's natural immune response, resulting in improved safety and efficacy profiles compared to non-human-derived antibodies. Moreover, the growing need for targeted treatment options to treat various diseases propels the segment.

Get Free Sample Report

Indication Segment Analysis

On the basis of indication, the global market is segregated into cancer, autoimmune diseases, inflammatory diseases, infectious diseases, and others. The cancer segment held a dominant share of the market in 2023, due to the growing demand for effective therapeutic interventions, such as long-acting monoclonal antibodies. These antibodies are important in cancer treatment by targeting specific antigens expressed on cancer cells, thereby inhibiting tumor growth and metastasis. Moreover, the growing prevalence of cancer among adults further fuels the need for long-acting monoclonal antibodies in the coming years.

• According to a report by the American Cancer Society on September 18, 2022, around 80,000 individuals aged between 20 and 39 are diagnosed with cancer every year in the US.

The autoimmune diseases segment is anticipated to expand at a substantial CAGR during the forecast period, owing to the high use of long-acting monoclonal antibodies to treat this disease. These antibodies offer a targeted treatment approach by modulating specific immune pathways involved in autoimmune disease pathogenesis. Furthermore, the rising prevalence of autoimmune diseases is expected to boost the demand for antibodies.

End-user Segment Analysis

Based on end-user, the long-acting monoclonal antibodies market is segmented into hospitals pharmacies, drug stores, e-commerce, and retail pharmacies. The e-commerce segment is projected to register a robust growth during the assessment years, owing to the growing popularity of online pharmacies and telemedicine services.

Patients conveniently order long-acting monoclonal antibodies-online to eliminate the need for in-person visits to traditional pharmacies. Additionally, competitive pricing, discounts, and home delivery options offered by e-commerce platforms propel the segment during the forecast period.

Get Free Sample Report

Regional Outlook

In terms of region, the global long-acting monoclonal antibodies market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America held a major market share in 2023, due to robust healthcare infrastructure and early adoption of advanced biologic therapies. Moreover, favorable regulatory policies and reimbursement frameworks in countries, including the US to facilitate timely approvals and market access for innovative therapies further fuel the market in this region.

The market in Asia Pacific is projected to grow at a significant pace in the years to come, owing to the increasing patient population suffering from chronic diseases. Countries, including China, Japan, and India are witnessing a rising prevalence of chronic diseases and infectious conditions.

This trend creates a high need for effective treatment options, including long-acting monoclonal antibodies to address the healthcare challenges. Additionally, government support for biopharmaceutical innovation is likely to fuel the development and the adoption of long-acting monoclonal antibodies in the region.

Get Free Sample Report

Segments

The long-acting monoclonal antibodies market has been segmented on the basis of

Source Type

• Chimeric
• Humanized
• Murine
• Human
• Others

Indication

• Cancer
• Autoimmune Diseases
• Inflammatory Diseases
• Infectious Diseases
• Others

End-user

• Hospitals Pharmacies
• Drug Stores
• E-commerce
• Retail Pharmacies

Region

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

Key Players

• Abbott
• Amgen Inc
• AstraZeneca
• Bayer AG
• GSK plc
• Lilly
• Merck KGaA
• Novartis AG
• Pfizer Inc

Competitive Landscape

Key players competing in the global long-acting monoclonal antibodies market are Abbott; Amgen Inc; AstraZeneca; Bayer AG; GSK plc; Lilly; Merck KGaA; Novartis AG; and Pfizer Inc. These companies use development strategies including mergers, acquisitions, partnerships, collaboration, and product launches to expand their consumer base worldwide.

• On December 8, 2021, AstraZeneca, a biopharmaceutical company, announced that the long-acting antibody combination EVUsheld (formerly known as AZD74442) granted emergency use authorization (EUA) by the US Food and Drug Administration (FDA). Evusheld is authorized for pre-exposure prophylaxis of COVID-19 in adults and adolescents who weigh 40kg or more have moderate to severe immune compromise and are aged 12 and older.